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ABSTRACT
RNA interference (RNAi) mediated by expression
of short hairpin RNAs (shRNAs) is a powerful tool
for efficiently suppressing target genes. The appro-
ach allows studies of the function of individual genes
and may also be applied to human therapy. However,
in many instances regulation of RNAi by administra-
tion of a small inducer molecule will be required.
To date, the development of appropriate regulatory
systems has been hampered by the few possibilities
formodification within RNA polymeraseIIIpromoters
capable of driving efficient expression of shRNAs.
We have developed an inducible minimal RNA poly-
merase III promoter that is activated by a novel
recombinant transactivator in the presence of doxy-
cycline (Dox). The recombinant transactivator and
the engineered promoter together form a system
permitting regulation of RNAi by Dox-induced
expression of shRNAs. Regulated RNAi was medi-
ated by one single lentiviral vector, blocked the
expression of green fluorescent protein (GFP) in a
GFP-expressing HEK 293T derived cell line and sup-
pressed endogenous p53 in wild-type HEK 293T,
MCF-7 and A549 cells. RNA interference was induced
in a dose- and time-dependent manner by admin-
istrationofDox,silencedtheexpressionofbothtarget
genes by 90% and was in particular reversible after
withdrawal of Dox.
INTRODUCTION
The efﬁcient and speciﬁc suppression of genes by RNAi (1)
constitutes a valuable new tool to study the physiological role
of individual genes in vitro and in vivo. The method may also
be applied to human therapy whenever genes involved in the
respective pathology have to be inhibited. Silencing of gene
expression by RNAi may be induced in target cells by express-
ing short hairpin RNAs (shRNAs) yielding small inhibitory
RNAs (siRNAs) after in situ cleavage (2). Since long poly A
tails strongly interfere with the silencing effect (3), shRNAs
are appropriately expressed by RNA polymerase III which
recognizes a simple run of T residues as a stop signal and
therefore does not require a poly A sequence to terminate
transcription. As a consequence, respective RNA polymerase
III promoters, such as the H1 promoter (4,5) or the U6 pro-
moter (6–8), are widely used to drive the production of
shRNAs. Both the H1 and the U6 promoters are constitutively
active, and therefore shRNAs can be expressed in a large
variety of cells in order to study the consequences of the stable
inhibition of target genes. However, constitutive gene silen-
cing cannot be used in the context of transgenic ‘knock-down’
animals when genes essential for cell survival, cell cycle regu-
lation and cell development are analyzed. Such studies require
conditional gene silencing induced by administration or with-
drawal of a small inducer molecule. Conditional suppression
of genes will also be important for therapeutic applications by
permitting termination of treatments at the onset of unwanted
side effects.
Conditional RNAi can be obtained by expression of
shRNAs fromamodiﬁedRNApolymerase IIIpromoterallow-
ing external control of its activity. A further requirement for
drug-induced transcriptional activity is the expression of a
heterologous transcription factor that speciﬁcally interferes,
in the presence or the absence of the inducer molecule,
with the activity of the modiﬁed promoter but does not interact
with the genome of the host cell. Because of their simple
structural organization RNA polymerase III promoters offer
only a few possibilities for modiﬁcation. The U6 promoter (9)
is composed of a TATA box, a proximal (PSE) and a distal
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doi:10.1093/nar/gkl034sequence element (DSE) that are each located at ﬁxed dis-
tances upstream from the transcription initiation site. The
space between the individual elements are restricted, thereby
limiting approaches based on steric interference with the
transcription initiation complex. Modiﬁcations may be applied
neither to the TATA box nor to the PSE since together they
form the essential core unit of the promoter recruiting the
transcription initiation complex.
In several studies (10–13) regulatory systems have been
proposed that employ RNA polymerase III promoter con-
structs controlled by reversible steric inhibition of the forma-
tionofthe transcriptioninitiationcomplex.However,Linetal.
observed severe leakiness when using these systems (14).
Anotherrecentattempt has been based on a Krab-Tet repressor
fusion protein which allows Dox-controlled inhibition of
the expression of shRNAs from a H1 promoter juxtaposed
with Tet-operon sequences (15). However, this approach
may be limited by secondary effects due to the inhibitory
activity of Krab on both RNA polymerase II and RNA poly-
merase III promoters over long distances (16). A third attempt
has been based on the activation of an engineered U6 promoter
by the recombinant transcription factor Gal4-Oct-2Q(Q!A)
that constitutively binds to four Gal-4 binding sites replac-
ing the DSE sequence in the promoter construct (17).
The transcription factor Gal4-Oct-2
Q(Q!A) comprises the
DNA binding unit of the transactivator Gal-4 from yeast
and an artiﬁcial transactivation domain referred to as the
Oct-2
Q(Q!A) domain. This transactivation domain is com-
posed of four copies of the peptide sequence Q
18III(Q!A)
comprising the amino acid residues 143 to 160 of the human
transcription factor Oct-2 in which all glutamine residues had
been changed to alanine. Regulated expression of the tran-
scription factor Gal4-Oct-2
Q(Q!A) under the control of the
ecdysone dependent regulatory system ultimately allowed
regulated production of shRNAs from the engineered U6 pro-
moter (18). However, the usefulness of this indirectly regu-
lated expression of shRNAs is limited since three vectors were
necessary to mediate expression of all the components
required.
In the present study, we set out to develop a regulatory
system that (i) allows efﬁcient regulation of RNAi, (ii) does
not cause secondary effects and (iii) can be delivered to target
cells by one single lentiviral vector. We based our approach
on a heterologous transactivator that conditionally binds in
the presence of a small inducer molecule to a minimal U6
promoter thereby activating transcription of shRNAs. We
investigated whether the Oct-2
Q(Q!A) domain can be con-
ditionally and functionally linked to a minimal U6 promoter
construct via the conditional DNA binding domain of the
transactivator rtTA2-M2 that derives from the Escherichia
coli Tet-repressor protein and mediates dimerization and
Doxycycline (Dox)-induced binding to tet operator sequences
with high afﬁnity (19). We replaced the three minimal VP
16-derived activation domains in rtTA2-M2 (20) by the
Oct-2
Q(Q!A) domain. For conditional binding to an indu-
cible minimal U6 promoter, the functional recognition sites
for Staf and Oct-1 within the DSE of the human U6 promoter
(21) were replaced by seven tet operator sequences. The modi-
ﬁed promoter and the engineered transcription factor were
capable of together forming a regulatory system allowing
conditional RNAi by Dox-dependent expression of shRNAs.
The regulatory system was delivered to target cells by one
single lentiviral vector.
MATERIALS AND METHODS
Plasmid constructions
The plasmids pUHR 10-3 and pUHRT 62-1, which contain
the components of the Tet regulatory system, were kindly
provided by H. Bujard (Zentrum fu ¨r Molekulare Biologie,
Heidelberg, Germany). The plasmid pcDNA-D that allows
the use of BbsI in subsequent cloning experiments was gen-
erated by self-ligation of the vector fragment obtained by
PstI digestion of the plasmid pcDNA 3 (Invitrogen, Cergy
Pontoise, France). The core unit of the human U6 promoter
that did not contain the functional binding sites for the tran-
scription factors Staf and Oct-1 (21) was ampliﬁed by PCR
from genomic DNA of HEK293T cells. The oligonucleotides
50-CGACGCGTTGCAGAGCTCGTTAGAGAGATAATTA-
GAATTAATTTGACTGTAAACACAAAG-30 and 50-CGG-
GATCCAGAAGACCACGGTGTTTCGTCCTTTCCACAA-
GAT-30 (Eurogentec, Angers, France) were the sense and
antisense primers respectively, and the DNA fragment amp-
liﬁed contained both a MluI and a SacI site upstream, and a
BbsI and a BamHI site downstream from the truncated
U6 promoter. The fragment was inserted between the MluI
and BamHI sites of pcDNA-D yielding the plasmid pcDNA-
DU6t. A MluI–SacI fragment containing seven tet operator
sequences was ampliﬁed by PCR from pUHR 10-3 and inser-
ted between the MluI and BamHI sites of pcDNA-DU6t to
give pcDNA-DU6min. The DNA fragment encoding shRNAs
designed to silence expression of green ﬂuorescent protein
(shGFP) was generated by annealing the oligonucleotides
50-ACCGCAAGCTGACCCTGAAGTTCTTCAAGAGAGA-
ACTTCAGGGTCAGCTTGCTTTTTCTCGAGG-30 and 50-
GATCCCTCGAGAAAAAGCAAGCTGACCCTGAAGTT-
CTCTCTTGAAGAACTTCAGGGTCAGCTTG-30. Anneal-
ing of the oligonucleotides 50-ACCGACTCCAGTGGTAA-
TCTACTTCAAGAGAGTAGATTACCACTGGAGTCTTT-
TTCTCGAGG-30 and 50-GATCCCTCGAGAAAAAGACT-
CCAGTGGTAATCTACTCTCTTGAAGTAGATTACCAC-
TGGAGT-30 yielded the DNA fragment encoding shRNAs
designed to silence expression of p53 (shp53). Both DNA
fragments encoding shRNAs were inserted into pcDNA-
DU6min linearized by BbsI–BamHI digestion. The resulting
plasmids were named pcDNA-DU6min-shGFP and pcDNA-
DU6min-shp53, respectively.
An EcoRI–BamHI fragment encoding the conditional DNA
binding domain of rtTA2-M2 (19) was ampliﬁed by PCR from
pUHRT 62-1 using the oligonucleotides 50-CGGAATTCAC-
CATGTCTAGACTGGACAAGAGCAAAG-30 and 50-CG-
GGATCCTGAAGACTACGGTCCGCCGCTTTCGCACTT-
TAGCTGT-30 asthesense andantisenseprimers,respectively.
Upstream from the BamHI site the fragment contained a stop
codon and a BbsI site allowing extension with a fragment
encoding additional amino acid residues. Insertion of the frag-
ment between the EcoRI–BamHI sites of pcDNA-D yielded
the plasmid pcDNA-D/rtTA2-M2trunc. The DNA fragment
coding the peptide sequence Q
18III(Q!A) was generated
by annealing the oligonucleotides 50-ACCGAACCTGTTCG-
CTCTCCCCGCTGCAACAGCGGGAGCCCTACTGACAT-
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CGGTGCTGATGTCAGTAGGGCTCCCGCTGTTGCAGC-
GGGGAGAGCGAACAGGTT-30 and was inserted into
pcDNA-D/rtTA2-M2trunc linearized by BbsI–BamHI diges-
tion. The resulting plasmid contained again a stop codon and
a BbsI site upstream from the BamHI site allowing further
rounds of extension with the same fragment. Extension with
the fragment encoding Q
18III(Q!A) was repeated three times
yielding the plasmid containing the rtTA2-Oct2 cDNA. The
sequence encoding rtTA2-Oct2 was recovered by EcoRI–
BamHI digestion and inserted into pD500rtTA2-M2-WPRE
(22) from which rtTA2-M2 had been removed by EcoRI–
BamHI digestion. A SalI–EcoRI fragment containing the
phosphoglyerate kinase (PGK) promoter was ampliﬁed by
PCR and inserted between the SalI–EcoRI sites upstream
from rtTA2-Oct2 yielding pD500PGK-rtTA2-Oct2-WPRE.
The cassettes allowing shRNA expression were recovered
from pcDNA-DU6min-shGFP and pcDNA-DU6min-shp53
by MluI–SpeI digestion and inserted into the lentivector
precursor plasmid pTrip-CMVmin-WPRE (22) from which
the element CMVmin had been removed by MluI–SpeI diges-
tion. The WPRE sequence was removed from the resulting
plasmids (pTrip-U6min-shGFP-WPRE and pTrip-U6min-
shp53-WPRE) by SpeI–KpnI digestion and replaced by the
rtTA2-Oct2 expression cassette recovered from pD500PGK-
rtTA2-Oct2-WPRE by NheI–KpnI digestion. The resulting
plasmids, pTrip-U6min-shGFP-PGK-rtTA2-Oct2-WPRE and
pTrip-U6min-shp53-PGK-rtTA2-Oct2-WPRE, were used for
the production of lentivirus vector particles.
The DNA fragment encoding the riboprobe for the detection
of the GFP silencing siRNAs was generated by annealing the
oligonucleotides 50-GATCCGCAAGCTGACCCTGAAGTT-
CTTCAAGAGAGAACG-30 and 50-AATTCGTTCTCTCTT-
GAAGAACTTCAGGGTCAGCTTGCG-30 and was inserted
between the BamHI–EcoRI sites of pcDNA 3. All plasmid
constructs were veriﬁed by sequencing using a ABI-PRISM
13100 DNA sequencer (Applied Biosystems, Courtabeuf,
France).
Cell culture, lentiviral transductions and
selection of transduced cells
The HEK 293T, MCF-7 and A549 cell lines were cultivated
at 37 C under a humidiﬁed atmosphere of 5% CO2 / 95% air
in DMEM supplemented with 10% fetal calf serum (FCS),
20 U/ml penicillin G and 20 mg/ml streptomycin sulfate.
Lentivirus vector particles were produced by transient cotrans-
fection of HEK 293T cells by the vector plasmid, an encap-
sidation plasmid (p8.7), and a VSV expression plasmid
(pHCMV-G) as described (23). Vector stocks were titered
by determination of the amount of the p24 capsid protein
using an HIV-1 core proﬁle enzyme linked immunosorbent
assay (ELISA) (Beckman Coulter, Roissy, France). For trans-
duction HEK 293T GFP cells were incubated overnight with
vector in the presence of 10 mg/ml DEAE dextran (Sigma-
Aldrich, St. Quentin Fallavier, France). Transduced cells
were selected after 5 days of cultivation in the presence of
6 mg/ml Dox using a FACSVantage SE cell-sorting instru-
ment (Becton Dickinson, Rungis, France). Selected clones
were expanded and analyzed by ﬂuorescence microscopy
and FACS.
Northern blot analysis
A
32P-labeled riboprobe was transcribed from the plas-
mid encoding the riboprobe using [a-
32P]ATP (Amersham
Biosciences, Orsay, France) and the Riboprobe System–T7
(Promega, Charbonnie `res, France). Small RNAs were isolated
from aliquots of 10
7 cells with the mirVana  PARIS  Kit
(Ambion, Huntingdon, UK). Samples containing 3.3 mg
of small RNAs were denatured by heating at 95 C for 5
min in the presence of 50% formamide. After electrophoresis
on a 15% polyacrylamide gel in the presence of 8 M urea the
RNA was stained with ethidium bromide and examined on a
transilluminator. The RNA was then transferred by
electroblotting to a BrightStar-Plus Nylon membrane
(Ambion), ﬁxed by ultraviolet (UV) crosslinking and hybrid-
ized to the probe. The resulting
32P-labeled RNA–RNA
hybrids were detected by autoradiography using Hyperﬁlm 
MP (Amersham Biosciences).
Western blot analysis
Cell extracts were prepared in lysis buffer [25 mM Tris–HCl
(pH 7.5), 1% Triton X-100, 0.5% sodium deoxycholate,
5 mM EDTA, 150 mM NaCl] containing a cocktail of protease
inhibitors (Roche, Meylan, France). The protein samples
(30 mg) were separated on SDS–9% polyacrylamide gels
and then transferred to Protan nitrocellulose membranes
(Schleicher and Schuell, Dassel, Germany) in an electroblot-
ting apparatus, using standard procedures (24). Immunodetec-
tion was performed as described previously (25), using a
monoclonal anti-p53 antibody (BD Biosciences, Erembode-
gem, Belgium), a monoclonal anti-actin antibody (Chemicon,
Hampshire, UK) and an anti-mouse Ig-horseradish peroxidase
(HRP) conjugate (Amersham Biosciences).
RESULTS AND DISCUSSION
To achieve regulated RNAi, we engineered a novel Tet-
dependent transactivator (Figure 1A) by linking the condi-
tional DNA binding domain of the tetracycline-dependent
transactivator rtTA2-M2 (19) to the Oct-2Q(Q!A) domain
(17) which is capable of speciﬁcally activating a minimal
U6 promoter (Figure 1A). An inducible minimal U6 promoter
was constructed by replacing the functional binding sites (21)
for the transcription factors Staf-1 and Oct-1 within the DSE
by seven tet operator sequences (Figure 1B). In the absence
of Dox the recombinant Tet-dependent transactivator will
not bind to the minimal U6 promoter (Figure 1C) and as a
consequence the shRNA coding sequence will not be tran-
scribed. In contrast, the Tet-dependent transactivator will
bind to the minimal U6 promoter in the presence of Dox
(Figure 1D), thereby activating the expression of shRNAs.
As a delivery system we designed a single lentivirus vector
by inserting two expression cassettes into its backbone
(Figure 2A). The ﬁrst cassette contained the minimal U6
promoter and was used to produce shRNAs. The second cas-
sette was employed to express the engineered transcription
factor rtTA2-Oct2 composed of the conditional DNA bind-
ing domain of rtTA2-M2 and the Oct-2
Q(Q!A) activation
domain. The transcription factor was constitutively tran-
scribed from the PGK promoter; and the polyA sequence of
the vector in the 30 long terminal repeat (LTR) was used for
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to enhance the expression of rtTA2-Oct2 and to stabilize
the RNA genome of the vector during the production of vector
particles in transiently transfected HEK 293T cells. A Flap
sequence was also included to improve transduction of
non-dividing cells (23). For safety reasons the U3 promoter
region was deleted from the 30 LTR so that the vector was
self-inactivating (27).
A ﬁrst vector contained a shRNA encoding sequence which
wasdesignedtosilencetheexpressionofGFPasdescribed(5).
A HEK 293T GFP cell-clone that stably expresses GFP as a
transgene was transduced with the vector construct. Cells were
cultivated in the presence and absence of Dox (6 mg/ml) prior
to isolating small RNAs from the cultures as well as from
controls (non-transduced HEK 293T GFP cells). ‘Northern
Blot’ analysis of the RNA samples revealed that siRNAs
designed to silence GFP were expressed in transduced cells
cultivated in the presence of Dox (Figure 2B). The siRNAs
were not detected in non-transduced cells. In transduced
cells cultivated without Dox no signal exceeding the detection
threshold was observed. ‘Northern Blotting’ did not allow
detection of shRNAs probably because of their rapid cleavage
into siRNAs by Dicer nuclease.
Subsequently, HEK 293T GFP cells were transduced with
various amounts of vector and incubated in the presence and
absence of Dox (6 mg/ml). Incubation with Dox reduced
the number of GFP-expressing cells by up to 60% as was
determined by FACS analysis (Figure 2C). The decrease in
GFP-positive cells correlated with the amount of vector
applied. The number of GFP-positive cells among transduced
cells incubated in the absence of Dox was 10–15% lower than
among non-transduced cells. This difference also correlated
with the amount of vector applied and may have been caused
Figure1.SchematicdiagramsillustratingtheregulatorysystemallowingDox-inducedRNAi.(A)PrimarystructureofthetransactivatorrtTA-Oct2composedofthe
conditional DNA binding domain of rtTA2-M2, and the Oct-2
Q(Q!A) domain mediating specific induction of a minimal RNA polymerase III promoter (17). (B)
StructureoftheminimalU6promoter:The202bpsequenceupstreamfromthetranscriptionstartsitewasderivedfromthehumanU6promoterandcontainsthePSE
andtheTATAbox.Upstreamfromthissequence,seventetoperatorsequences(tetOs)havebeeninsertedtoallowconditionalbindingofthetransactivator.(C)Inthe
absence of Dox (off state), rtTA-Oct2 does not bind to the operator sequences and hence shRNAs are not synthesized. (D) In the presence of Dox (on state), the
transactivator binds and thereby activates the expression of shRNAs designed to induce the degradation of the respective target mRNAs.
Figure 2. A single lentiviralvector mediates Dox-regulatedRNAi. (A) Design
of the vector: LTR, y and Flap are sequences derived from HIV-1 (the LTRs,
thepackagingsequenceandthecentralFlapelement,respectively).P U6 minand
P PGK are the Tet-regulated minimal U6 promoter and the phosphoglycerate
kinase promoter; WPRE is the Woodchuck hepatitis virus responsive element;
rtTA-Oct2,thecDNAencodingthetranscriptionfactorrTA-Oct2;andshRNA,
the sequence encoding shRNAs. (B and C) Experimental validation of regu-
lated RNAi using a vector that expresses shRNAs designed to silence the
expression of GFP. (B) ‘Northern blot’ analysis of Dox-regulated expression
of siRNAs from the vector. HEK 293T GFP cells (1 · 10
5) were incubated for
24 h with and without vector corresponding to 141 ng of protein p24, and
cultivated in the presence and absence of 6 mg/ml Dox for 7 days. Then, small
RNAs were isolated from the cells and probed for siRNAs designed to silence
the expression of GFP. 5S-rRNA detected by ethidium bromide staining of the
polyacrylamide gel served as an internal control to show equal loading. (C)
Experimental validation of RNAi-mediated silencing of GFP. HEK 293T GFP
cells (8 · 10
4) were incubated overnight with various quantities of vector
expressed as ng of protein p24, and cultivated in the absence (grey bars)
and in the presence (white bars) of 6 mg/ml Dox for 5 days prior to FACS
analysis. Values are averages of percentages of GFP-positive cells ± SE,
n ¼ 3.
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To establish uniform conditions for precise characterization
of the regulatory system, cell clones were ampliﬁed from indi-
vidual transduced cells. Several clones were obtained that
displayed Dox-regulated expression of GFP (see Supplement-
ary Table). Fluorescence microscopy of a representative clone
(C9) demonstrated that GFP was only expressed in the absence
of Dox (Figure 3A). We then used FACS analysis to study the
effect of Dox on the expression of GFP. The addition of Dox
to the cells was followed by a signiﬁcant decrease in GFP
ﬂuorescence within 24 h; after 5–6 days the reduction of
GFP ﬂuorescence was 90% (Figure 3B). In the absence of
Dox there was no change in GFP ﬂuorescence during the
incubation. To determine the minimal concentration of Dox
required to induce RNAi, cells of the clone C9 were incubated
with various concentrations of Dox (Figure 3C). A concentra-
tion of 6 mg/ml was required to induce a 90% suppression of
GFP within 5 days. Lower concentrations of Dox were either
ineffective or caused incomplete or delayed RNAi. To test
inducible RNAi for reversibility, cells of the clone C9 were
cultivated for 5 days in the presence of Dox. Then Dox was
removed, and the expression of GFP was followed. GFP
ﬂuorescence had increased signiﬁcantly 48 h after the removal
of Dox (Figure 3D); however, incubation without Dox for
5–6 days was required to restore maximal expression of
GFP. No increase in GFP ﬂuorescence was detected in cells
incubated with Dox throughout the experiment.
The next step was to investigate whether the regulation
system can be employed for the silencing of other target
genes. As a target we chose the p53 gene because of detectable
expression in mammalian cells, availability of reliable anti-
bodies to monitor levels of the protein, and the existence of an
efﬁcient shRNA (2). Moreover, in a recent study genetic dele-
tion of p53 suppressed neurodegeneration in animal models
of Huntington’s disease (28). Thus, local and regulated down-
regulation of p53 may potentially constitute a novel gene
therapy approach for the treatment of Huntington disease
patients. We constructed a second vector, which contained
a shRNA encoding sequence designed to silence expression
of human p53 as described (2). HEK 293T cells, MCF-7 cells
and A549 cells were transduced with various amounts of vec-
torandincubatedinthepresenceandabsence ofDox(6mg/ml)
for 5–7 days before protein was extracted from the cultures as
well as from non-tansduced controls. ‘Western blot’ analysis
of protein samples containing identical amounts of protein
Figure3.CharacterizationofDox-regulatedRNAiinarepresentativecell-clone(C9):(A)Microscopicanalysisofcellsincubatedinthepresenceorintheabsenceof
6 mg/mlDox at 72 h after induction.(B) Time courseof Dox-inducedRNAi: RNAiwasinduced ornot inducedat day0 by administration of 6 mg/mlDox and mean
intensitiesofGFPfluorescenceweremeasuredbyFACSanalysisatvarioustimesafterinduction.ClosedtrianglesrepresentintensitiesofcellsincubatedwithDox,
open triangles givethose of untreatedcells. The fluorescence intensity observedat day 0 was definedas100%, valuesare means ± SE, n ¼ 3. (C) Mean intensities
(± SE, n ¼ 3) of GFP fluorescence obtained by FACS analysis of cells cultivated for 5 days in the presence of various concentrations of Dox. The fluorescence
intensityinuntreatedcellswasdefinedas100%.(D)ReappearanceofGFPfluorescenceafterwithdrawalofDox:priortotheanalysis,cellswerecultivatedfor5days
in the presence of 6 mg/ml Dox. At day 0, Dox was withdrawn or not withdrawn and the mean fluorescence intensity was followed by FACS analysis. Closed
rhomboidsrepresentvaluesfromcellsthatwerenottreatedwithDoxfromday0,openrhomboidsgivevaluesfromcellsincubatedwith6mg/mlDoxthroughoutthe
experiment. The fluorescence intensity measured 8 days after removal of Dox was defined as 100%, values are means ± SE, n ¼ 3.
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duced cells were incubated in the presence of Dox (Figure 4).
An up to 90% inhibition of the expression of p53 was observed
in Dox treated cultures of transduced cells as assessed by
densitometric analysis of the Blot data. No down-regulation
of p53, or at best some minimal silencing because of leakage
expression of shRNAs, was obtained when transduced cells
were cultivated in the absence of Dox. The expression of p53
was not reduced when non-transduced cells were incubated
in the presence of Dox (6 mg/ml).
Considered together, our ﬁndings indicate that the engin-
eered minimal U6 promoter was conditionally reactivated
by Dox-controlled binding of rtTA2-Oct2 containing the
Oct-2
Q(Q!A) domain for transactivation. The minimal U6
promoter and the recombinant transcription factor together
formed a regulatory system allowing conditional RNAi by
Dox-controlled production of shRNAs. In particular, the sys-
tem allowed the expression of the reporter transgene GFP
as well as the expression of the endogenous gene p53 to be
rendered under external regulation by means of administration
of Dox. To fully induce RNAi a Dox concentration of 6 mg/ml
was necessary which is more than 10-fold the concentration
required to activate a minimal (cytomegalovirus) CMV pro-
moter by the transactivator rtTA2-M2 (19). Indeed, the
responsiveness to Dox was similar to that of the Tet-
dependent regulatory system which, by using rtTA as a trans-
activator, requires a Dox concentration of 1 mg/ml to induce
the expression of transgenes in vitro (29). That system was
successfully applied in the context of transgenic mice (30).
Taken into account that an at least 70% induction of RNAi
was already observed in the presence of 1 mg/ml of Dox
(Figure 3C), the regulation system presented here holds prom-
ise to be also applicable to animal studies. However, further
studies using transgenic mice are required to examine the
efﬁciency of Dox-regulated RNAi in vivo.
Nevertheless the ﬁnding that 6 mg/ml of Dox are necessary
to fully induce RNAi in cultured cells is an unexpected result.
It may be caused by the Oct-2
Q(Q!A) transactivation
domain which may affect the afﬁnity for Dox by interference
with either the accessibility or the structure of the Dox binding
site. Secondary intramolecular effects of the transactivation
domain on characteristics of the conditional DNA binding
domain can in particular not be ruled out because of the overall
hydrophobicity of the Oct-2
Q(Q!A) domain.
The Oct-2
Q(Q!A) domain is composed of four copies of
the peptide sequenceQ
18III(Q!A) which comprises 18 amino
acid residues (17). Fourteen out of the 18 amino acid resi-
dues are non-polar and hydrophobic. Four amino acid residues
are polar, and charged amino acid side chains are lacking
(Figure 1A). Because of these characteristics the Oct-
2
Q(Q!A) domain probably forms a hydrophobic patch
which facilitates the formation of the transcription initiation
complex after binding in a correct steric orientation to the
minimal U6 promoter. The peptide sequence Q
18III(Q!A)
corresponds to the amino acid residues 143 to 160 of the
human transcription factor Oct-2 in which all glutamine resi-
dues have been changed to alanine. Since the mutations
change 6 amino acid residues out of 18, the Q
18III(Q!A)
sequence may almost be considered as an individual synthetic
peptide sequence. In particular, it is noteworthy that the Q!A
mutations remove the capacity of transactivating RNA poly-
merase II promoters (17). For this reason and because we
use the weak PGK promoter to drive expression of the trans-
activator, the regulatory system reported in the present study
should not cause secondary effects by transactivation of pro-
moters in the vicinity of the vector integration site.
The regulatory system that we developed requires expres-
sion of only one heterologous transactivator and can therefore
be delivered to target cells by one single lentiviral vector. It
is by far more complicated to establish conditional RNAi by
ecdysone-regulated expression of the Gal4-Oct-2
Q(Q!A)
transcription factor that in turn activates a minimal U6 pro-
moter construct by constitutive binding. This indirect regulat-
ory approach required expression of additional heterologuos
components, and as a consequence three vectors were neces-
sary to deliver regulated RNAi to target cells (18). The deliv-
ery of our regulatory system by one single lentiviral vector
willsigniﬁcantlyfacilitatethe applicationofconditionalRNAi
in many instances.
In summary, we have developed a regulatory system allow-
ing Dox-controlled expression of shRNAs and demonstrated
inducible, reversible and stable RNAi in mammalian cells.
Figure4.‘Westernblot’analysisdemonstratingsilencingofp53byDox-regulatedRNAiin(A)HEK293Tcells,(B)MCF-7cellsand(C)A549cells.Cells(1 · 10
5)
were incubated overnight with indicated quantities of vector, expressed as ng of protein p24, and then cultivated in the absence and in the presence of 6 mg/ml Dox.
Aftera5day(MCF-7andA549cells)anda7daycultivation(HEK293Tcells),proteinwasextractedfromthecellsandanalyzedbyimmunoblotting.Bothp53and
actin were detected; the latter served as a control to demonstrate equal loading.
e37 Nucleic Acids Research, 2006, Vol. 34, No. 5 PAGE 6 OF 7The system may allow the expression of any gene to be ren-
dered under external control by means of administration of
Dox. Inducible RNAi will ﬁnd applications in genetic studies
using transgenic animals and will also open the door for novel
gene therapy approaches such as the treatment of Huntington’s
disease by local and regulated silencing of p53.
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